Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10878556 | 0.86 | CLEC4M (0.71) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL5133700 | 0.86 | CLEC4M (0.71) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL8912313 | 0.86 | ALDH1A1 (0.61) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| Ethyl Acetate SCHEMBL30402120 | 0.85 | ALDH1A1 (0.79) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL8132372 | 0.85 | KDM4E (0.71) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL28287784 | 0.85 | CLEC4M (0.82) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL16011747 | 0.84 | ALDH1A1 (0.73) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL9269461 | 0.84 | ALDH1A1 (0.73) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL22492440 | 0.84 | CLEC4M (0.80) | CLEC4MKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1244789 | 0.84 | CLEC4M (0.80) | CLEC4MKDM4EALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0343574-B1 | 4(1H)-quinolone derivatives | KIRIN BREWERY (JP) | 1994-07-27 | — | — | EP | claimed |
| US-20170174632-A1 | 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH ZURICH (CH) | 2017-06-22 | — | — | US | disclosed |
| US-20170174632-A1 | 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH ZURICH (CH) | 2017-06-22 | — | — | US | disclosed |
| US-20170174632-A1 | 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH ZURICH (CH) | 2017-06-22 | — | — | US | disclosed |
| EP-3166930-A1 | 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH Zürich (CH) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016005419-A1 | 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH ZURICH (CH) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016005419-A1 | 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | ETH ZURICH (CH) | 2016-01-14 | — | — | WO | disclosed |
| EP-2966062-A1 | 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy | ETH Zurich (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966062-A1 | 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy | ETH Zurich (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011022216-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-24 | — | — | WO | disclosed |
| US-5438064-A | For suppressing the binding of bradykinins to pain receptors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0343574-B1 | 4(1H)-quinolone derivatives | KIRIN BREWERY (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5081121-A | Cardiotonic agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0343574-A1 | 4(1H)-quinolone derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174632-A1 | 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY | CNR2, CNR1, OXER1 | CLEC4M 1665/4885KDM4E 2146/4885ALDH1A1 3320/4885 |
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HMOX2, HMOX1, MPO | CLEC4M 2408/4885KDM4E 1780/4885ALDH1A1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.